Great West Life Assurance Co Can buys $241,219,643 stake in Pfizer (PFE)

Pfizer (PFE) : Great West Life Assurance Co Can scooped up 1,360,953 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 6,835,354 shares of Pfizer which is valued at $241,219,643.Pfizer makes up approximately 0.70% of Great West Life Assurance Co Can’s portfolio.

Other Hedge Funds, Including , Mission Wealth Management reduced its stake in PFE by selling 322 shares or 0.87% in the most recent quarter. The Hedge Fund company now holds 36,576 shares of PFE which is valued at $1,290,767. Pfizer makes up approx 0.32% of Mission Wealth Management’s portfolio. Polaris Greystone Financial Group sold out all of its stake in PFE during the most recent quarter. The investment firm sold 9,295 shares of PFE which is valued $328,021.Compass Capital Management Inc reduced its stake in PFE by selling 1,850 shares or 11.99% in the most recent quarter. The Hedge Fund company now holds 13,574 shares of PFE which is valued at $500,745. Pfizer makes up approx 0.09% of Compass Capital Management Inc’s portfolio.Strs Ohio reduced its stake in PFE by selling 107,325 shares or 2.44% in the most recent quarter. The Hedge Fund company now holds 4,294,228 shares of PFE which is valued at $158,242,302. Pfizer makes up approx 0.68% of Strs Ohio’s portfolio.Daiwa Sb Investments Ltd. reduced its stake in PFE by selling 7,340 shares or 46.57% in the most recent quarter. The Hedge Fund company now holds 8,420 shares of PFE which is valued at $304,130. Pfizer makes up approx 0.09% of Daiwa Sb Investments Ltd.’s portfolio.

Pfizer closed down -0.51 points or -1.44% at $34.93 with 3,05,40,494 shares getting traded on Monday. Post opening the session at $35.28, the shares hit an intraday low of $34.71 and an intraday high of $35.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *